The development of dual‐target HDAC6 inhibitors for cancer therapy is an area of active research, with promising candidates such as dual HDAC6/PI3K inhibitors, dual HDAC6/mTOR inhibitors, dual HDAC6/BRD4 inhibitors, and dual HDAC6/HSP90 inhibitors in various stages of development. The gene discussed is HDAC6; the disease is cancer.